IONS
IONIS PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$44.38
+3.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +27.2%
- EBITDA
- +14.0%
- EPS
- +9.0%
Three-year CAGR
- Revenue
- +17.1%
- EBITDA
- +19.6%
- EBIT
- +19.6%
- Net income
- +16.1%
- EPS
- +21.7%
- Free cash flow
- +41.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026